Cargando…

Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study

BACKGROUND: Aplastic anemia (AA) is a rare disease in which hematopoietic stem cells are severely diminished resulting in hypocellular bone marrow and pancytopenia. Etiology of AA includes auto immunity, toxins, infection, ionizing radiation, drugs and rare genetic disorders, but in the majority of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jalaeikhoo, Hasan, Khajeh-Mehrizi, Ahmad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430492/ https://www.ncbi.nlm.nih.gov/pubmed/25970182 http://dx.doi.org/10.1371/journal.pone.0126925

Ejemplares similares

Aplastic anemia: immunosuppressive therapy in 2010
por: Risitano, Antonio M., et al.
Publicado: (2011)

Immunosuppressive therapy for aplastic anemia: a single-center experience from western India
por: Shah, Sandip, et al.
Publicado: (2018)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

Immunosuppressive Treatment in Children with Acquired Aplastic Anemia
por: Yıldırmak, Yıldız, et al.
Publicado: (2012)

Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study
por: Liu, Qi, et al.
Publicado: (2022)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia
por: Dhingra, Gaurav, et al.
Publicado: (2023)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
por: yang, B., et al.
Publicado: (2022)

Thymoma followed by aplastic anemia - two different responses to immunosuppressive therapy
por: de Castro, Murilo Antunes, et al.
Publicado: (2011)

Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia
por: Chen, Hai-Fei, et al.
Publicado: (2014)

Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study
por: Jalaeikhoo, Hasan, et al.
Publicado: (2019)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study
por: Yang, Wenrui, et al.
Publicado: (2023)

Single-cell RNA Sequencing Reveals Novel Cellular Factors for Response to Immunosuppressive Therapy in Aplastic Anemia
por: Jang, Jinho, et al.
Publicado: (2023)

The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea.
por: Kim, Inho, et al.
Publicado: (2003)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: A meta-analysis of retrospective studies
por: Wang, Jia, et al.
Publicado: (2020)

A cohort study of immune and hematopoietic functionality changes in severe aplastic anemia patients treated with immunosuppressive therapy
por: Guan, Jing, et al.
Publicado: (2019)

Predictive value of T cell receptor repertoire profiling for immunosuppressive therapy in severe aplastic anemia
por: Chen, Cunte, et al.
Publicado: (2023)

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
por: Contejean, Adrien, et al.
Publicado: (2019)

Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study
por: Shen, Yingying, et al.
Publicado: (2023)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
por: Zhang, Zhuxin, et al.
Publicado: (2023)

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022)

Idiopathic severe aplastic anemia with a delayed response to immunosuppressive therapy: a case report
por: Alzahrani, Nujood, et al.
Publicado: (2018)

Magnetic resonance imaging of the bone marrow after bone marrow transplantation or immunosuppressive therapy in aplastic anemia.
por: Park, J. M., et al.
Publicado: (2001)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia
por: Dong, Peiyuan, et al.
Publicado: (2022)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy
por: Wang, Huaquan, et al.
Publicado: (2015)

Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia
por: Zhang, Xia, et al.
Publicado: (2018)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
por: Li, Ruixin, et al.
Publicado: (2022)

Ocular manifestations of idiopathic aplastic anemia: retrospective study and literature review
por: Mansour, Ahmad M, et al.
Publicado: (2014)

Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia
por: Chen, Lingyun, et al.
Publicado: (2023)

Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
por: Huang, Junbin, et al.
Publicado: (2021)

Aplastic Anemia in China
por: Liu, Chunyan, et al.
Publicado: (2018)

Osteonecrosis of the hip in patients with aplastic anemia.
por: Park, Jeongmi, et al.
Publicado: (2002)

Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020)

Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia
por: Zhou, Fang, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qguurpesooac7e6vg443je2h6d